Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
1. A method for treating multiple myeloma consisting of administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor alpha (RARα) selective agonist and a proteasome inhibitor, wherein the CYP26-resistant RARα selective agonist is a compound having the structure of formula I,
wherein R 1 is H or C 1-6 alkyl;
R 2 and R 1 are independently H or F; and
R 4 is a halogen, and
optionally, at least one additional anti-cancer agent selected from the list consisting of etoposide, an anthracycline, idarubicin, daunorubicin, mitoxantrone, cytarabine, a combination of an anthracycline, cytarabine and etoposide, a demethylating agent, 5-azacytidine, decitabine, a tyrosine kinase inhibitor, a BCR-ABL inhibitor, a Flt3 inhibitor, a cKit inhibitor, an IDH1/2 inhibitor, a JAK2 inhibitor, a BTK inhibitor, anti-CD33 mAb, anti-CD20 mAb, anti-CD19 mAb, anti-CD30 mAb, anti-PD1 mAb, anti-CTL4 mAb, lenalidomidel, pomalidomide, cyclophosphamide, bevacizumab, vincristine, a corticosteroid, bleomycin, adriamycin, bendamustin, fludarabine, G-CSF, GM-CSF, Epo, and combinations thereof,
whereby as a result of the treatment the tumor burden, including multiple myeloma (MM) B cell burden, is reduced in the subject.
2. The method according to claim 1 , wherein administration of an effective dose of the CYP26-resistant RARα selective agonist and the proteasome inhibitor results in the elimination of minimal residual disease or cancer stem cells from the bone marrow niche of the subject, thereby improving the disease-free survival of the subject.
3. The method according to claim 1 , consisting of administration of the effective dose of the CYP26-resistant RARα selective agonist, the proteasome inhibitor, and the at least one additional anti-cancer agent, wherein administration of the effective dose of the CYP26-resistant RARα selective agonist results in sensitization of minimal residual disease to the at least one additional anticancer agent, whereby combination of the CYP26-resistant RARα selective agonist with the at least one additional anticancer agent results in improvement of the disease-free survival of the subject.
4. The method according to claim 1 , whereby, as a result of the treatment, reduction of tumor burden is greater than the additive effect of the CYP26-resistant RARα selective agonist and the proteasome inhibitor acting alone.
5. The method according to claim 1 , wherein the CYP26-resistant RARα selective agonist is
6. The method according to claim 1 , wherein the proteasome inhibitor is bortezomib.
7. The method of claim 6 , wherein the CYP26-resistant retinoic acid receptor alpha (RARα) selective agonist is IRX5183.
8. The method according to claim 1 , wherein the subject has minimal residual disease.
9. A method of sensitizing multiple myeloma cells in bone marrow to treatment with a proteasome inhibitor, consisting of administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor alpha (RARα) selective agonist, wherein the CYP26-resistant RARα selective agonist is a compound having the structure of formula I,
wherein R 1 is H or C 1-6 alkyl;
R 2 and R 3 are independently H or F; and
R 4 is a halogen;
wherein the subject in need thereof is receiving treatment for multiple myeloma with a proteasome inhibitor, and
optionally, at least one additional anti-cancer agent selected from the list consisting of etoposide, an anthracycline, idarubicin, daunorubicin, mitoxantrone, cytarabine, a combination of an anthracycline, cytarabine and etoposide, a demethylating agent, 5-azacytidine, decitabine, a tyrosine kinase inhibitor, a BCR-ABL inhibitor, a Flt3 inhibitor, a cKit inhibitor, an IDH1/2 inhibitor, a JAK2 inhibitor, a BTK inhibitor, anti-CD33 mAb, anti-CD20 mAb, anti-CD19 mAb, anti-CD30 mAb, anti-PD1 mAb, anti-CTL4 mAb, lenalidomidel, pomalidomide, cyclophosphamide, bevacizumab, vincristine, a corticosteroid, bleomycin, adriamycin, bendamustin, fludarabine, G-CSF, GM-CSF, Epo, and combinations thereof.
10. The method according to claim 9 , wherein administration of an effective dose of the CYP26-resistant RARα selective agonist while receiving the proteasome inhibitor results in the elimination of minimal residual disease or cancer stem cells from the bone marrow niche of the subject, thereby improving the disease-free survival of the subject.
11. The method according to claim 9 , wherein administration of an effective dose of the CYP26-resistant RARα selective agonist while receiving the proteasome inhibitor and the at least one additional anti-cancer agent, results in sensitization of minimal residual disease to the at least one additional anticancer agent, whereby combination of the CYP26-resistant RARα selective agonist with the at least one additional anticancer agent results in improvement of the disease-free survival of the subject.
12. The method according to claim 9 , wherein the CYP26-resistant RARα selective agonist is
13. The method according to claim 9 , wherein the proteasome inhibitor is bortezomib.
14. The method according to claim 13 , wherein the CYP26-resistant retinoic acid receptor alpha (RARα) selective agonist is IRX5183.
15. The method according to claim 9 , wherein the subject has minimal residual disease.
16. The method according to claim 9 , whereby, as a result of treatment, reduction of tumor burden is greater than the additive effect of the CYP26-resistant RARα selective agonist and the proteasome inhibitor acting alone.